biopharmaceuticals

AstraZeneca’s COPD drug posts strong Phase 3 results, boosting blockbuster hopes

AstraZeneca on Tuesday released full results from two late-stage trials showing its experimental drug tozorakimab reduced dangerous flare-ups in a broad population of patients with chronic obstructive pulmonary disease, reinforcing the company's projection of more than $5 billion in peak…